Research review priorities
Supplement research priorities
These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.
- priority dossiers
- 148
- claim-level questions
- 444
- study extraction underway
- 148
01 / PRIORITY
How priorities were selected
Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.
02 / EXTRACTION
What happens next
For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.
Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.Tart cherry
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
Sleep and uric-acid signals are small, heterogeneous, and do not establish insomnia or gout treatment.
Questions being reviewed
- Does tart cherry improve objective sleep and daytime function in adequately powered insomnia trials?
- Which exercise-recovery or uric-acid effects are clinically meaningful and do they reduce gout flares?
- How do juice, concentrate, capsule, sugar, calories, dose, medicine interactions, and kidney disease affect use?
Methylsulfonylmethane (MSM)
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Direct MSM osteoarthritis evidence is extremely sparse and pooled evidence with related DMSO was neither statistically nor clinically significant.
Questions being reviewed
- Does MSM alone improve clinically meaningful osteoarthritis pain and function versus placebo?
- Which dose and duration have independent replication rather than multi-ingredient confounding?
- What gastrointestinal, allergy, pregnancy, anticoagulant, and long-term safety limits apply?
Chondroitin sulfate
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Pooled short-term osteoarthritis pain benefit is offset by low-quality, heterogeneous evidence and strong product-quality dependence.
Questions being reviewed
- Does pharmaceutical-grade chondroitin improve clinically meaningful pain and function, and for which joints?
- Does it slow structural progression, and why do source, purity, molecular weight, and retail quality matter?
- What anticoagulant, bleeding, shellfish/source, asthma, diabetes, and surgery limits apply?
Undenatured type II collagen (UC-II)
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Small short-term trials suggest knee-osteoarthritis symptom benefit, but evidence is limited and does not establish cartilage repair.
Questions being reviewed
- Does UC-II improve clinically meaningful knee pain and function versus placebo?
- Does it alter cartilage or disease progression, and are branded chicken-derived products interchangeable?
- What poultry allergy, autoimmune disease, pregnancy, duration, and medicine limits apply?
Oral hyaluronic acid
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
A small heterogeneous review reports symptom improvements, but pooled magnitude, bias, structural effects, and low-back-pain evidence remain weak.
Questions being reviewed
- Does oral hyaluronic acid improve clinically meaningful osteoarthritis pain and function versus placebo?
- How do molecular weight, source, absorption, dose, and any cartilage effects differ across products?
- What allergy, pregnancy, cancer-history, interaction, and long-term safety limits apply?
03 / SOURCES
Research standards
The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.